Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Price Passes Above 200 Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $46.53 and traded as high as $52.07. Global X Genomics & Biotechnology ETF shares last traded at $52.07, with a volume of 13,658 shares trading hands.

Global X Genomics & Biotechnology ETF Stock Performance

The business has a 50 day simple moving average of $47.06 and a 200-day simple moving average of $46.53. The firm has a market cap of $58.32 million, a price-to-earnings ratio of -22.25 and a beta of 1.21.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after buying an additional 48,394 shares in the last quarter. Wealth Management Partners LLC purchased a new stake in Global X Genomics & Biotechnology ETF in the 1st quarter valued at $244,000. Creative Financial Designs Inc. ADV raised its position in Global X Genomics & Biotechnology ETF by 4.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after buying an additional 481 shares during the last quarter. U.S. Capital Wealth Advisors LLC bought a new position in Global X Genomics & Biotechnology ETF during the 4th quarter valued at $575,000. Finally, IFP Advisors Inc lifted its stake in Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after acquiring an additional 489 shares in the last quarter. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.